NCI-H1781 Xenograft Model Service for NSCLC

The NCI-H1781 xenograft model represents a well-established HER2-driven lung adenocarcinoma platform harboring a HER2 exon 20 insertion mutation, offering a clinically relevant preclinical substrate for evaluating HER2-targeted tyrosine kinase inhibitors, antibody-drug conjugates, and combination strategies in NSCLC. Alfa Cytology leverages this authenticated HER2-amplified cell line—paired with rigorous cell banking, optimized implantation protocols, and integrated pharmacodynamic analysis—to advance your preclinical programs targeting oncogenic HER2 alterations with reproducible, publication-ready data.

Overview of NCI-H1781 Xenograft Model for NSCLC

The NCI-H1781 cell line was established in November 1987 by A.F. Gazdar and J.D. Minna at the National Cancer Institute from pleural effusion metastatic cells of a 66-year-old Caucasian female smoker (60 pack-years) diagnosed with stage 3B bronchoalveolar carcinoma. This line is molecularly defined by HER2 (ERBB2) amplification and overexpression, coupled with a HER2 exon 20 insertion mutation (A775insV, G776C, also designated G776VC) that constitutively activates the receptor tyrosine kinase domain. The line also harbors a TP53 mutation, contributing to genomic instability. The donor patient had received both chemotherapy and radiation therapy prior to tissue collection, a clinical history that may have influenced the therapeutic sensitivity profile of the derived line. Both EGFR and KRAS remain wild-type, positioning NCI-H1781 as a pure HER2-driven model without confounding canonical oncogene mutations.

Fig 1. Tarloxotinib-E suppressed NCI-H1781 (HER2 ex20ins) xenograft growth in vivo, while continuous exposure generated NCI-H1781-TR resistant cells with reduced tarloxotinib sensitivity — a model for studying HER2-mutant NSCLC acquired resistance. (Estrada-Bernal, Adriana, et al., 2021)

In immunodeficient hosts, NCI-H1781 demonstrates robust tumorigenicity with reliable engraftment when 5×10⁶ cells are implanted subcutaneously with Matrigel support. Tumors become palpable within 7–10 days and progress with consistent kinetics. Preclinical validation has demonstrated profound sensitivity to HER2-directed therapies: the irreversible pan-HER inhibitor afatinib suppresses proliferation in parental cells, while next-generation HER2-selective inhibitors such as sevabertinib and zongertinib drive tumor regression in vivo at clinically relevant doses. The model also responds to antibody-drug conjugates targeting Ly6E and Nectin-4, reflecting broader receptor tyrosine kinase dependency. These properties render the NCI-H1781 xenograft an indispensable tool for preclinical evaluation of HER2 exon 20 insertion inhibitors, HER2-selective TKIs, and ADC-based combination strategies in a molecularly defined lung adenocarcinoma context.

Cell Line Information: NCI-H1781

The table below consolidates the essential biological, genetic, and operational characteristics of the NCI-H1781 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers a comprehensive NCI-H1781 xenograft program encompassing authenticated cell banking, mycoplasma and sterility verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our standardized workflows—refined across numerous receptor tyrosine kinase-driven lung cancer studies—ensure consistent engraftment, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H1781 Xenograft Model Construction

Construction of the NCI-H1781 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H1781 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 10% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation against the published ATCC profile, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 200×g for 5 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold HBSS at a concentration of 5×10⁷ cells/mL for a final inoculum of 5×10⁶ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female SCID-beige or BALB/c nude mice are acclimatized for a minimum of seven days. Under aseptic conditions, 100–200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 5 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 7–10 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (HER2, p-HER2, p-ERK, p-AKT, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq). Serum is collected for pharmacokinetic correlation where applicable.

Fig 2. NCI-H1781 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology established the NCI-H1781 subcutaneous xenograft to assess the anti-tumor efficacy of a novel HER2-selective tyrosine kinase inhibitor in a HER2 exon 20 insertion-mutant lung adenocarcinoma context. Following robust tumor engraftment in female SCID-beige mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via oral gavage on a once-daily schedule for 21 days at two escalating dose levels alongside a zongertinib reference arm. Longitudinal monitoring revealed dose-dependent tumor growth inhibition in treated animals relative to vehicle controls, with the highest dose cohort demonstrating sustained suppression throughout the treatment window. At study termination, harvested tumors underwent comprehensive histopathological review and biomarker analysis, including HER2 and p-HER2 immunostaining to confirm target engagement, p-ERK and p-AKT staining to evaluate downstream pathway modulation, Ki-67 quantification to assess proliferative inhibition, and TUNEL assay to assess apoptotic induction. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and immunohistochemistry images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H1781 xenograft program provides access to a purpose-built infrastructure optimized for HER2-driven lung cancer preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H1781 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation against the ATCC reference profile and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics in this HER2-amplified adenocarcinoma model, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent HER2 inhibitor, HER2-targeted ADC, combination, and dose-escalation designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including HER2, p-HER2, p-ERK, p-AKT, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline targets the HER2-driven NSCLC landscape—whether advancing a next-generation HER2 exon 20 insertion inhibitor, exploring HER2-targeted ADC strategies, or evaluating combination blockade in a wild-type EGFR and KRAS context—Alfa Cytology offers the NCI-H1781 xenograft expertise to advance your preclinical objectives with scientific rigor. Reach out to our scientific team today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.